Reperfusion injury future or investigational therapies

Revision as of 19:31, 15 May 2012 by Kristin Feeney (talk | contribs) (Created page with "{{Reperfusion therapy}} '''Editors-In-Chief:''' {{AC}}; C. Michael Gibson, M.S., M.D. [mailto:Mgibson@perfuse.org] ==Overview== ==Future Directions== While there has be...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Template:Reperfusion therapy

Editors-In-Chief: Anjan K. Chakrabarti, M.D. [1]; C. Michael Gibson, M.S., M.D. [2]

Overview

Future Directions

While there has been significant progress made in understanding repercussion injury, from molecular mechanisms to bedside clinical interventional, there are several areas that warrant further study. Some of these topics were outlined by the 2010 National Heart, Lung, and Blood Institute Workshop on Cardioprotection[1], and include:

  1. Identifying the molecular and subcellular mechanisms responsible for postconditioning, remote conditioning, and preconditioning.
  2. Determining whether the protective mechanism triggered by remote conditioning is humoral, neural, or both.
  3. Investigating whether age, obesity, and diabetes mellitus may attenuate the beneficial effects of cardioprotective strategies.
  4. Developing additional pharmacological strategies that mimic, synergize, or augment the protection exerted by conditioning protocols in conjunction with repercussion.
  5. Establishing a cardioprotective clinical trial network concurrent with the existing and complementary preclinical network (CAESAR) to test promising cardioprotective agents and strategies in patients in the setting of both acute myocardial infarction and cardiac surgery.

References

  1. Schwartz Longacre L, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E; et al. (2011). "New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop". Circulation. 124 (10): 1172–9. doi:10.1161/CIRCULATIONAHA.111.032698. PMID 21900096.